$ATYR

ATYR Financials: Income Statement, Balance Sheet & Cash Flow

This article provides a detailed financial overview of Atyr Pharma Inc (ATYR), including its income statement, balance sheet, and cash flow statement, along with key financial ratios. It highlights the company's financial health signals, annual and quarterly metrics, and frequently asked questions about its performance. The analysis indicates weak overall financial health with low profitability and negative cash flow, despite strong liquidity and low leverage.

Original reporting
Published Mar 3, 2026, 8:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 3, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ATYR Financials: Income Statement, Balance Sheet & Cash Flow — source image
Decision brief

The 30-second read

$ATYRBearishLow
01

Why it matters

Financial weakness may lead to further stock decline, affecting investor confidence and sector perception.

02

Market read

Financial data indicates limited short-term trading opportunities; more relevant for long-term risk assessment.

03

What to watch

Potential upcoming catalysts or partnership news not reflected in current financials could alter outlook.

Timing: Limited short-term trading relevance; primarily long-term concern.

Background

Recent financial statements reveal ongoing challenges for ATYR, including low profitability and negative cash flow, despite liquidity.

Company-level read

Ticker impact

$ATYRBearishMedium confidence
Context

High relevance due to direct financial data impact.

Expected impact

Potential further decline in stock price due to ongoing financial struggles.

Evidence & confidence

The analysis is based on recent financial reports indicating poor profitability and cash flow issues, which historically correlate with downward price movements. However, lack of current market price data limits precision.

Market effects

Weak financials in biotech/life sciences sector may pressure sector indices.

Limited regional impact; company-specific issue.

Minimal global market relevance; focused on company fundamentals.

Counterpoint

If company management implements strategic turnaround, stock could stabilize or improve over the medium term.

Key entities

  • Atyr Pharma Inc

    Biotech company focusing on rare disease treatments.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.